01—Abstract
Summary
Summary of the 8-K/A filed January 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Viatris Inc. filed this Amendment No. 1 to its October 2, 2023 Form 8-K to report that it exercised its option on January 26, 2024, requiring Cooper Consumer Health SAS and certain affiliates (the Buyer Parties) to purchase and assume substantially all of Viatris' over-the-counter products business and related assets and liabilities.
The option was exercised after completion of applicable employee consultation procedures in France, Italy and the Netherlands. On January 29, 2024, Viatris, Viatris Italia S.r.l., Ipex AB and the Buyer Parties entered into the Transaction Agreement, under which the terms described in the Initial 8-K apply. Consummation remains subject to closing conditions, including regulatory consents and approvals from the European Commission (under European antitrust laws and the EU Foreign Subsidiaries Regulation) and the French Ministry of Economy, consents or renewals under certain material supply, license and service contracts relating to the business (subject to limits on their aggregate economic impact), and other customary conditions.
The parties have already received regulatory consents and approvals from the Presidency of the Italian Council of Ministries and the Commission for Protection of Competition of the Republic of Serbia. For investors, the filing confirms that the divestiture has moved from a binding offer to a signed agreement, but it does not state closing timing or the purchase price in this document. The filing also includes standard forward-looking statement cautions, noting risks that the transaction may not complete on expected timelines or at all, that expected proceeds may not be realized, and that impairment or other losses may arise from the sale.
02—Key points
Key Highlights
- Viatris exercised its option on January 26, 2024, to require Cooper Consumer Health SAS and certain affiliates to purchase and assume substantially all of its over-the-counter products business.
- The Transaction Agreement was entered into on January 29, 2024, among Viatris, Viatris Italia S.r.l., Ipex AB and the Buyer Parties.
- The option was exercised only after completion of employee consultation procedures where required by local law, including in France, Italy and the Netherlands.
- Closing remains subject to European Commission and French Ministry of Economy approvals, along with consents under certain material supply, license and service contracts.
- Regulatory consents and approvals have been received from the Presidency of the Italian Council of Ministries and the Commission for Protection of Competition of the Republic of Serbia.
- Consents, renewals or extensions of specified contracts are subject to limitations on their aggregate economic impact, per the Transaction Agreement.
- Exhibit 2.1, the Transaction Agreement, has omitted annexes, schedules and exhibits under Item 601(a)(5) of Regulation S-K, with copies available to the SEC on request.
03—Questions
Frequently Asked Questions
What business is Viatris selling?
Viatris is selling substantially all of its over-the-counter products business and related assets and liabilities to Cooper Consumer Health SAS and certain of its affiliates.
Is the transaction complete?
No. The filing states that consummation remains subject to various closing conditions, including regulatory consents and approvals from the European Commission and the French Ministry of Economy, consents under certain material contracts, and other customary conditions. Consents from the Italian Council of Ministries Presidency and Serbia's Commission for Protection of Competition have already been received.
What steps led to the signed Transaction Agreement?
Viatris first reported on October 2, 2023, that Cooper Consumer Health SAS had made a binding offer granting Viatris an option to require the sale. Viatris exercised that option on January 26, 2024, after completing required employee consultations, and the parties signed the Transaction Agreement on January 29, 2024.
What risks could prevent investors from realizing the expected benefits?
The filing cautions that the transaction may not be completed on expected timelines or at all, that closing conditions may not be satisfied or waived, that expected proceeds or total transaction value may not be realized (including due to purchase price adjustments or unmet contingent consideration conditions), that intended benefits may not be achieved, and that goodwill or other impairment charges or losses may result.
04—Continue